HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,915.00
+60.00 (1.56%)
At close: Dec 5, 2025
-60.77%
Market Cap 477.03B
Revenue (ttm) 114.33B
Net Income (ttm) -178.33B
Shares Out 121.85M
EPS (ttm) -1,434.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 487,007
Average Volume 846,311
Open 3,895.00
Previous Close 3,855.00
Day's Range 3,760.00 - 3,920.00
52-Week Range 3,105.00 - 11,940.00
Beta -0.13
RSI 46.76
Earnings Date Nov 13, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.